financetom
Business
financetom
/
Business
/
CoreWeave Insider Sold Shares Worth $7,886,788, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CoreWeave Insider Sold Shares Worth $7,886,788, According to a Recent SEC Filing
Sep 2, 2025 12:35 AM

03:30 AM EDT, 09/02/2025 (MT Newswires) -- Michael N Intrator, 10% Owner, Director, Chief Executive Officer and President, on August 27, 2025, sold 82,455 shares in CoreWeave ( CRWV ) for $7,886,788. Following the Form 4 filing with the SEC, Intrator has control over a total of 7,153,330 Class A common shares of the company, with 7,153,330 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1769628/000141588925023330/xslF345X05/form4-08302025_120831.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brookfield Wealth Solutions Announces Just Shareholder Approval of Acquisition
Brookfield Wealth Solutions Announces Just Shareholder Approval of Acquisition
Sep 21, 2025
BROOKFIELD, NEWS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Just Group plc (“Just”) shareholders voted in favor of Brookfield Wealth Solutions’ (“BWS”) acquisition of the company at the Court Meeting and General Meetings held on September 19, 2025. Sachin Shah, CEO of Brookfield Wealth Solutions ( BNT ), said: “We are pleased to receive the endorsement from Just shareholders. This milestone...
Skye Bioscience Says Liver Disease Drug Candidate Safe, Well Tolerated in Phase 1B Clinical Trial
Skye Bioscience Says Liver Disease Drug Candidate Safe, Well Tolerated in Phase 1B Clinical Trial
Sep 21, 2025
09:01 AM EDT, 09/19/2025 (MT Newswires) -- Skye Bioscience ( SKYE ) said Friday that results from the phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease, or MASLD, demonstrated that the drug candidate was safe and well-tolerated. Results also indicated that nimacimab has predictable pharmacokinetics and low immunogenicity, according to the company. The company also said...
Soccer-Man United boss Amorim denies Ratcliffe meeting hints at trouble
Soccer-Man United boss Amorim denies Ratcliffe meeting hints at trouble
Sep 21, 2025
(removes extrraneous letter in Ratcliffe in paragraph four) MANCHESTER, England, Sept 19 (Reuters) - Manchester United ( MANU ) boss Ruben Amorim insists he still has the backing of Jim Ratcliffe, shooting down suggestions that the co-owner's visit to the club's Carrington Training Ground on Thursday was anything more ominous than a regular meeting. The Portuguese manager has overseen one...
US SEC chair: Market can decide 'proper cadence' of company reports
US SEC chair: Market can decide 'proper cadence' of company reports
Sep 21, 2025
WASHINGTON, Sept 19 (Reuters) - Investors and banks are likely to help set any new timeline for public company reporting as regulators press ahead on President Donald Trump's bid to end quarterly reports, U.S. Securities and Exchange Commission Chairman Paul Atkins told CNBC on Friday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved